Compare ENTX & ACR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTX | ACR |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | Israel | United States |
| Employees | N/A | 4 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.4M | 146.1M |
| IPO Year | 2015 | N/A |
| Metric | ENTX | ACR |
|---|---|---|
| Price | $2.78 | $14.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $9.00 | ★ $24.50 |
| AVG Volume (30 Days) | ★ 3.5M | 21.8K |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $42,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $41.00 | ★ $19.59 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $14.71 |
| 52 Week High | $4.20 | $24.61 |
| Indicator | ENTX | ACR |
|---|---|---|
| Relative Strength Index (RSI) | 60.29 | 24.72 |
| Support Level | $1.26 | N/A |
| Resistance Level | $3.22 | $18.56 |
| Average True Range (ATR) | 0.36 | 0.74 |
| MACD | 0.02 | -0.27 |
| Stochastic Oscillator | 40.43 | 1.60 |
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding, and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralized debt obligations, and private equity investments mainly issued by financial institutions.